NEWPORT BIOLOGICS MODULE

UNIQUE INTELLIGENCE ON BIOLOGIC AND BIOSIMILAR DRUGS

HOW YOU BENEFIT

- Integrates seamlessly with your *Newport Premium*™ data
- Updated monthly so you have the latest information
- Comprehensive training and technical support so you get the most value from your subscription
- Integrated on-line help to get you to the information you need quickly

WHERE YOU CAN USE IT

- Strategic Planning
- Product Targeting
- Business Development
- Competitive Intelligence

LET US KNOW WHAT YOU THINK

If you have suggestions for the next series of *Newport* modules, please send an email to ts.NPContentSupport@thomsonreuters.com with your ideas and our Product Management staff will respond to you directly.

MAKE BETTER, FASTER DECISIONS

Biosimilar drugs are fast becoming a reality in global pharmaceutical markets. The passing of the 2010 Healthcare Reform Act in the US and decrease in the number of small molecule opportunities are expected to fuel increased activity in this area for generics, traditionally small-molecule focused innovators, and biotech companies.

The *Newport Biologics Module* contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing follow-on opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is US BLA (Biologics License Application) data for drugs approved through this regulatory route.

The *Newport Biologics Module* is an optional subscription module that may be added to your *Newport Premium* subscription for an additional annual charge. *Newport Premium* includes information about active substance and contract manufacturers, patents and exclusivities, regulatory filings, and worldwide sales and launch data. With the majority of biosimilar activity in the industry being driven through deals, the existing *Newport Generic Deals Module* makes an excellent companion for the new biologics content.

STRATEGIC PLANNING, PRODUCT TARGETING

- Identify opportunities that match your strategic needs and strengths
- Adjust your research timing, investments, priorities, and resources based on unique manufacturing process data, sales trends, and patent expiries

BUSINESS DEVELOPMENT

- Profile candidate products for acquisition, alliances, licensing, or supply and manufacturing
- Identify potential partners for collaboration
- Evaluate candidate products against industry-best process data

COMPETITIVE INTELLIGENCE

- Identify potential competitors based on bio-manufacturing capabilities and activities
- Identify early minor market biosimilar launches
- Complete visibility of patent landscape, exclusivities, and other key competitive data worldwide



Analyze multiple potential bio-manufacturing processes for each drug



Review process steps, generic sequences, starting materials, and related patents

THOMSON REUTERS REGIONAL OFFICES

North America
Philadelphia +1 855 260 5607
+1 215 386 0100

Latin America
+55 11 8370 9845

Europe, Middle East and Africa
London +0 800 145 6412

Asia Pacific
Singapore +65 6775 5088
Tokyo +81 3 5218 6500

For a complete office list visit:
ip-science.thomsonreuters.com/contact

PH1108276

Copyright © 2012 Thomson Reuters

THOMSON REUTERS™